Dexorgen

Dexorgen is a private biotechnology company founded in 2018, specializing in live-cell assay platforms for drug discovery, particularly in the GPCR and PDE target spaces. Its patented ACTOne technology enables real-time, high-throughput measurement of intracellular cAMP changes, offering a physiologically relevant screening environment. The company operates as a platform and services provider, offering cell lines, assay kits, and contract research to pharmaceutical, biotech, and academic clients. While not a therapeutic developer itself, Dexorgen's tools are critical for identifying novel compounds in areas like asthma, cardiovascular, and CNS diseases.

ACTOne Technology: A live-cell assay platform using a modified cyclic nucleotide-gated (CNG) ion channel as a biosensor to detect real-time changes in intracellular cAMP/cGMP levels. Enables high-throughput screening for GPCR modulators and PDE inhibitors in physiologically relevant cellular environments.

Dexorgen competes in the drug discovery tools segment against giants like Revvity, Thermo Fisher Scientific, and Eurofins Discovery, which offer broad portfolios of biochemical and cell-based assays. Its direct competitors are specialized assay providers such as DiscoverX (now part of Eurofins) and Molecular Devices, which also offer functional GPCR assay platforms. Dexorgen's differentiation is its specific focus on real-time, live-cell cAMP detection via CNG channels for both GPCR and PDE targets.